Moderna Swings to 3Q Profit, Driven by Updated Covid-19 Vaccine
The biotech company, which makes the Spikevax RNA-based Covid-19 vaccine, reported net income of $13 million, or 3 cents a share, compared with a loss of $3.6 billion, or $9.53 a share, in the same quarter last year. Analysts had forecast a loss of $1.96 a share, on average, according to FactSet.